ArticleFrontiers in endocrinology2026
Association between body mass index and anti-Müllerian hormone in women with ovarian endometrioma and dermoid cyst.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adiposity influences reproductive function via endocrine and immune pathways. The association between body mass index (BMI) and anti-Müllerian hormone (AMH) in endometriosis is uncertain, and BMI may not fully capture adiposity-related biology relevant to ovarian reserve. We assessed whether BMI is associated with AMH in untreated ovarian endometrioma and whether this differs from dermoid cysts. Methods: Retrospective single-center cohort of 951 newly diagnosed, reproductive-age women from January 1, 2020 to December 31, 2023 (717 endometrioma; 234 dermoid). AMH was measured on one platform; imaging included transvaginal ultrasonography with MRI or contrast-enhanced abdominopelvic CT as needed. Multivariable linear regression modeled log-AMH versus BMI, adjusting for age, diagnosis, cyst size and laterality, parity, smoking, alcohol use, cycle regularity, and cycle length. Nonlinearity was screened with restricted cubic splines; piecewise models explored age breakpoints. An interaction term tested whether the BMI effect differed by diagnosis. Effects are reported as percent change in AMH per 1 kg/m². Results: Women with endometrioma were older (31.9 vs 29.9 years; P<.001) and had lower BMI (21.1 vs 22.4 kg/m²; P<.001) than those with dermoid. Median AMH was 2.52 vs 2.70 ng/mL; age-adjusted geometric means did not differ (P = .245). Piecewise modeling identified earlier age breakpoints in endometrioma (35.7 years) than dermoid (40.4 years). In fully adjusted models, each 1 kg/m² higher BMI was associated with 2.3% lower AMH (P = .003). Group-specific estimates were -1.9% per kg/m² in endometrioma (P = .060) and -2.8% per kg/m² in dermoid (P = .009); the BMI×diagnosis interaction was not significant (P = .538). Model fit was modest (adjusted R²=0.22), and BMI explained 1% of AMH variance (partial R²=0.01). Sensitivity analyses restricting the BMI range yielded consistent directions of effect with attenuation at lower BMI. Conclusions: Across endometrioma and dermoid cysts, BMI shows a weak inverse association with AMH without evidence of between-group differences. Given BMI's minimal explanatory value, local ovarian factors may more strongly determine ovarian reserve in endometrioma. Limited numbers of obese participants constrain inference at higher BMI; studies with broader BMI distributions and integrated metabolic profiling are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.